Scientists use drug to unravel Insulin's secrets in prediabetes

NCT ID NCT06354088

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how the hormone insulin controls blood sugar and fat in healthy adults and those at risk for type 2 diabetes. Researchers will give participants a single dose of a drug called alpelisib, which blocks some of insulin's effects, to see if the liver can still make fat even when it stops responding to insulin's sugar-lowering signal. The goal is to better understand insulin resistance and related conditions like prediabetes and fatty liver disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INSULIN RESISTANCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fatty liver disease hyperinsulinism Insulin Resistance metabolic dysfunction-associated steatotic liver disease Obesity obesity disorder Overweight prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Columbia University Irving Medical Center

    RECRUITING

    New York, New York, 10032, United States

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact